Drugs from Bugs: The Anti-Inflammatory Drugs of Tomorrow

描述（由申请人提供）：本提案要求支持由Padraic G. Fallon、Grant McFadden和Amanda E.I. Proudfoot Fichard组织的题为“来自细菌的药物：未来的抗炎药物”的Keystone专题会议，该会议将于2011年4月3日至7日在犹他州雪鸟市举行。最近的一个全球趋势是，越来越少的新疗法正在从管道进入临床。这促使药物研究和开发部门在扩大对新药的研究方面采用不那么传统的方法。“细菌药物：未来的抗炎药物”专题讨论会将探讨从病原体中发现新药的日益增长的机会，或“细菌药物”方法。人类基因组是人类适应环境因素进化的产物，传染性病原体施加了强大的选择压力。当今一些主要的免疫介导疾病与进化为对病原体作出反应的基因有关。通过了解病原体如何调节和篡夺免疫系统，以及从病原体中识别功能分子，可以开发新的治疗策略和新药。事实上，新一代病原体衍生的免疫调节分子目前正处于临床试验阶段。在这次会议上，主要专家将介绍利用病原体作为新疗法源泉的现状。该论坛将为工业界与学术界合作开发药物发现新策略提供机会。这次会议将汇集跨学科的科学家交流和分享想法，从而促进合作，为未来制定新的药物战略。这次会议与Keystone早期药物发现发展方法专题讨论会同时举行，将大大增加跨学科互动的机会。

DESCRIPTION (provided by applicant): This proposal requests support for a Keystone Symposia meeting entitled Drugs from Bugs: The Anti- Inflammatory Drugs of Tomorrow, organized by Padraic G. Fallon, Grant McFadden and Amanda E.I. Proudfoot Fichard, which will be held in Snowbird, Utah from April 3 - 7, 2011. A recent global trend is that fewer novel therapeutics are progressing from the pipeline to the clinic. This has prompted the drug research and development sector to adopt less conventional approaches in broadening the search for new drugs. The Keystone Symposia meeting on Drugs from Bugs: The Anti-Inflammatory Drugs of Tomorrow will examine the growing opportunities for discovery of novel drugs from pathogens, or the "drugs from bugs" approach. The genome of man is the product of the evolution of humans adapting to environmental factors, with infectious pathogens exerting potent selective pressure. Some of the major immune-mediated diseases of today are associated with genes that evolved to respond to pathogens. Novel therapeutic strategies and new drugs can be developed by both understanding how pathogens modulate and usurp the immune system, and also by identifying the functional molecules from pathogens. Indeed, a new generation of pathogen-derived immune modulating molecules is now in clinical trials. In this meeting leading experts will present the current status of the use of pathogens as a wellspring for new therapeutics. This forum will be an opportunity for industry to engage with academics for the development of novel strategies for drug discovery. This meeting will bring together cross-disciplinary scientists to exchange and share ideas, and thereby foster collaborations directed at the generation of new drug strategies for the future. Opportunities for interdisciplinary interactions will be significantly enhanced by the co-location of this meeting with the Keystone Symposia meeting on Evolving Approaches to Early-Stage Drug Discovery. PUBLIC HEALTH RELEVANCE: Advances in drug discovery technology have raised expectations that the global drug development industry will deliver "magic bullets" or "wonder drugs" for a range of diseases, in particular inflammatory disorders. In fact, fewer novel therapeutics are progressing from the pipeline to the clinic, and the lack of new treatments is a growing health concern due to the worldwide increase in the incidence of a range of many diseases, such as asthma and inflammatory bowel disease. The Keystone Symposia meeting on Drugs from Bugs: The Anti- Inflammatory Drugs of Tomorrow will examine the growing opportunities for discovery of novel drugs from pathogens, or the "drugs from bugs" approach.